Talking With PA Maureen E. Thyne About Ruxolitinib for Myelofibrosis
May 27th 2016Though there are few therapeutic options for patients with myelofibrosis, ruxolitinib (Jakafi) represents an important look towards the future, according to Maureen E. Thyne, a physician assistant in the Outpatient Leukemia Service at Weill Cornell Medical College.
Video-Based Behavioral Therapy May Ease "Chemobrain" in Breast Cancer Survivors
May 26th 2016Research suggests that 25% to 40% of individuals receiving chemotherapy experience persistent mild to moderate cognitive changes, and a study of breast cancer survivors suggests that a new type of psychotherapy delivered by videoconference may help reduce these effects, often referred to as “chemobrain.”
Prognosis Discordance Prevalent Among Decision-Makers at the End-of-Life
May 25th 2016Researchers conducted interviews of patients’ decision-makers to determine how well their understanding of a patient’s prognosis aligned with the physician’s prognostic estimate. The patients were receiving care in the intensive care unit and were identified by physicians as having a high risk of death.
Physical Functioning Worse, Depression Elevated, in Some Older Survivors, Study Finds
May 24th 2016Older patients with cancer experience greater declines in physical functioning, according to a recent study published in the journal Cancer. Further, these patients also were at an increased risk of depression.
FDA Approves Nivolumab for Hodgkin Lymphoma
May 17th 2016The FDA granted nivolumab (Opdivo) accelerated approval for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin (Adcetris).
Aromatase Inhibitors, Tamoxifen Similar for Cardiovascular Disease Risk
May 13th 2016A retrospective analysis conducted by researchers at Kaiser Permanente and UCLA has concluded that patients with breast cancer treated with aromatase inhibitors (AIs) as adjuvant endocrine therapy were at equal risk of serious cardiovascular disease (CVD) events as those treated with tamoxifen.
ADT Increases Risk for Depression in Elderly Men With Localized Prostate Cancer
May 4th 2016Although androgen deprivation therapy (ADT) has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether ADT causes clinically significant depression.
Nightly Fasting Found Beneficial to Reduce Breast Cancer Recurrence
May 2nd 2016A study of more than 2400 women with early-stage breast cancer has found that those who fasted 13 hours or more at night reduced their risk of breast cancer recurrence, findings that suggest prolonging the nightly fasting interval may offer a relatively safe nonpharmacologic way for women with early breast cancer to lower their risk of disease recurrence.